Skip to content
My WebMD Sign In, Sign Up
H.E.A.

Interactions

Ergotamine Derivatives/Selected Potent CYP3A4 Inhibitors

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

When these two medicines are taken together, your body may not process ergotamine or ergotamine derivatives properly.

What might happen:

Your blood levels of ergotamine or ergotamine derivative may increase and cause toxic effects.

What you should do about this interaction:

Contact your healthcare professional (e.g. doctor or pharmacist) right away about using these medicines together. Your doctor may not want you to take your ergotamine derivative while you are taking your other medicine.If you experience chest pain; change in heartbeat; numbness and tingling of hands, feet, or face; pain in arms, legs, or lower back; itching; or other symptoms while taking both of these medicines, contact your doctor.Your healthcare professionals (e.g. doctor or pharmacist) may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

References:

1.D. H. E. 45 (dihydroergotamine mesylate) US prescribing information. Xcel Pharmaceuticals September, 2002.

2.Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir) prescribing information. Gilead Sciences, Inc. October, 2013.

3.Cafergot (ergotamine tartrate and caffeine) Suppositories US prescribing information. Novartis Pharmaceuticals Corporation June, 2002.

4.Methergine (methylergonovine maleate) US prescribing information. Novartis Pharmaceuticals Corporation June, 2012.

5.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, expect as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

More about Drugs and Medications

URAC: Accredited Health Web Site HONcode Seal AdChoices